Moderna (MRNA) Total Debt (2025 - 2026)

Moderna's (MRNA) quarterly Total Debt came in at $590.0 million in Q1 2026, little changed on a QoQ basis from $590.0 million in Q4 2025.

Moderna (MRNA) Total Debt (2025 - 2026) Analysis & Trends

Moderna (MRNA) has 2 years of Total Debt data on file, last reported at $590.0 million in Q1 2026.

  • On a quarterly basis, Total Debt changed N/A year-over-year to $590.0 million in Q1 2026; TTM through Mar 2026 was $590.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $590.0 million, changed N/A from the prior year.
  • Total Debt for Q1 2026 stood at $590.0 million, roughly flat from $590.0 million in the prior quarter.
  • Over the last five years, Total Debt for MRNA reached as high as $590.0 million in Q4 2025 and fell as low as $590.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 959.06 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Moderna 22.52 Bn 17.32 Bn -566.00 Mn 590.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 590.00 Mn
Dec 31, 2025 590.00 Mn